Schwannoma is defined in the packet as a benign, usually encapsulated, slow growing tumor composed of Schwann cells that affects peripheral and cranial nerves. The definition states that it recurs infrequently and that only rare cases associated with malignant transformation have been reported. The packet categorizes its prevalence as uncommon, with an estimate of approximately 1 to 9 per 100,000 (the measure type is not specified). Listed synonyms include neurilemmoma, neurinoma and benign schwannoma, and listed subtypes include vestibular-region entities such as acoustic neuroma, trigeminal schwannoma, plexiform schwannoma and schwannomatosis.

No phenotype annotations, characteristic findings or ages of onset are included in this packet. The definition describes a slow growing tumor of peripheral and cranial nerves, and further clinical features are not certified here.

The packet lists no associated genes, no inheritance pattern and no molecular mechanism for schwannoma. The definition identifies the tumor as composed of Schwann cells. A genetic cause or pattern of inheritance is not described in this packet.

The packet does not include diagnostic methods or criteria for schwannoma, so diagnostic approaches are not certified in this packet.

The packet lists no FDA-approved treatment records for schwannoma. FDA orphan drug designation, which is not an approval, is recorded for live attenuated Salmonella enterica serovar Typhimurium, sponsored by Mulberry Biotherapeutics, Inc., for treatment of schwannoma. Other treatment information is not certified in this packet.

Beyond the definition's statements that the tumor is slow growing, recurs infrequently, and has rarely been associated with malignant transformation, the packet does not include natural history or outcome information, so further prognostic detail is not certified in this packet.

The packet includes ClinicalTrials.gov records with recruiting and active statuses. Examples include NCT01199978, a phase 2 study of fractionated proton radiation therapy and hearing outcomes in vestibular schwannoma sponsored by Massachusetts General Hospital (active, not recruiting); NCT06517888, a phase 1 anti-VEGF gene therapy trial for vestibular schwannoma sponsored by Akouos, Inc. (recruiting); NCT04374305, the phase 2 INTUITT-NF2 study of targeted therapies in NF2-related schwannomatosis, led by Scott R. Plotkin (recruiting); and NCT05684692, the phase 2 STARFISH screening trial for pain relief in schwannomatosis, sponsored by Massachusetts General Hospital (recruiting). Trial titles indicate the topics studied and do not establish efficacy. A ClinicalTrials.gov search link for schwannoma is provided in the packet; no patient organizations are listed.